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Drosophila melanogaster is an experimentally tractable model organism that has been used successfully to model aspects of
many human neurodegenerative diseases. Drosophila models of tauopathy have provided valuable insights into tau-mediated
mechanisms of neuronal dysfunction and death. Here we review the findings from Drosophila models of tauopathy reported over
the past ten years and discuss how they have furthered our understanding of the pathogenesis of tauopathies. We also discuss the
multitude of technical advantages that Drosophila oﬀers, which make it highly attractive as a model for such studies.
1. Tauopathies
Tauopathies are a group of neurodegenerative diseases char-
acterised by abnormally hyperphosphorylated and insoluble
aggregates of the microtubule-associated protein tau [1].
They include diseases where the tau pathology is the
only neuropathological hallmark (such as frontotemporal
dementia, Pick’s disease, corticobasal degeneration, progres-
sive supranuclear palsy, and others), as well as diseases
where the tau pathology coexists with another pathology
(such as Alzheimer’s disease (AD), Parkinson’s disease, and
Creutzfeldt-Jakob disease amongst others). The nature of the
tau aggregates, their constituent tau isoforms, and the brain
region they deposit in varies depending on the disease. The
tau aggregates are found in neuronal as well as glial cells, and
the brain regions aﬀected include hippocampal/entorhinal
regions, cortical regions, and mid/hind brain regions. Thus,
the clinical symptoms range from cognitive impairments to
locomotor disabilities [2].
Despite the varied neuropathological and clinical pro-
files, all tauopathies are characterised by the same tau
aberrations: abnormal and hyperphosphorylation [3], mis-
folding [4], and aggregation [5]. Mutations in the tau gene,
which give rise to frontotemporal dementia with Parkinson-
ism linked to chromosome 17 (FTDP-17) [6], are capable of
inducing these tau modifications. Since they are associated
with degeneration and dementia, these changes in tau are
likely to be responsible for these pathologies. However,
the processes that trigger tau abnormalities in sporadic
tauopathies have not yet been identified. Moreover, despite
studies to investigate the physiological consequences of these
tau aberrations in various models of tauopathy, their patho-
logical significance is still debated. The emerging realisation
that tau has additional functions in the neuron, other than
microtubule stabilisation (reviewed in Morris et al., 2011
[7]), implies that tau abnormalities are likely to impact
upon more than one neuronal process. Thus, there may be
multiple mechanisms mediating tau toxicity in tauopathies.
In addition to dissecting mechanisms of tau toxicity, research
eﬀorts are also focused on further understanding of other
aspects of tau biology, including its turnover, its regula-
tion by myriad posttranslational modifications, (other than
phosphorylation), and its interaction with other disease-
associated proteins like amyloid beta (Aβ).
Numerousmodels of tauopathy, in both vertebrates [8, 9]
and invertebrates [10, 11], have been generated to address
links between tau biology and pathology. Drosophila occu-
pies a unique position amongst model organisms because of
the rich history of its use as a genetic model and hence its
powerful genetic tractability. In this paper, we first describe
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some of the attributes of Drosophila that make it an excellent
choice of organisms to study tauopathies, to test hypotheses
about pathogenesis, identify disease mechanisms, and even
screen disease-modifying drugs. Then we go on to review
important insights about tauopathies that have come from
Drosophila models over the past ten years.
1.1. Drosophila as a Model Organism. Aside from the very
obvious advantages aﬀorded by its small size, inexpen-
sive maintenance, rapid propagation, and short life span,
Drosophila melanogaster has a multitude of technical advan-
tages. It is not the intention of this paper to discuss these
in any great detail, but merely to highlight the reasons
why Drosophila may be particularly attractive for modelling
aspects of human diseases such as tauopathies and how
its attributes can enable further insights to be gained into
disease mechanisms.
1.1.1. Insights from Drosophila Are Relevant to Humans.
Drosophila has played a pivotal role in deciphering numer-
ous fundamental biological processes ranging from our
understanding of genetics to our current knowledge of
important physiological processes including embryogenesis,
cell signalling, aging, and circadian rhythms, to name
just a few (for a more comprehensive review of the rich
history of the use of Drosophila as a model in modern
biology see Pandey and Nichols 2011 [12]). The fact that
the underlying cell/molecular bases for these fundamental
biological events are essentially the same from Drosophila
to mammals highlights the striking conservation of basic
physiological processes across the species. This is further
underlined by the finding, upon the comparison of the
completed human and fly genomes, that over 75% of genes
implicated in human disease, have Drosophila orthologues
[13]. This opens up the exciting possibility that just as
the simplicity of Drosophila was exploited to gain insight
into important mammalian biological processes, we may
now use Drosophila models to shed light on mechanisms
underpinning mammalian diseases. Indeed, aspects of many
common human diseases, including neurodegenerative dis-
eases (such as Alzheimer’s, Huntington’s, Parkinson’s—
reviewed in Marsh and Thompson, 2006 [14] and Iijima-
Ando and Iijima, 2010 [15]), seizure disorders, and aﬀective
disorders (such as alcohol addiction [16] and cancers [17])
have been successfully modelled in Drosophila. Furthermore,
there is scope for the development of additional Drosophila
models of human disease including cardiovascular disease,
inflammatory disease and diabetes (reviewed in Pandey and
Nichols 2011 [12]).
1.1.2. Drosophila Is Highly Genetically Tractable. 100 years of
extensive use as an experimental genetic model (as described
above), as well as a sequenced and highly annotated genome,
provides Drosophila researchers with many elegant and
powerful genetic tools (see Table 1 and for a comprehensive
review of these techniques see Nichols 2006 [18]). Most
of these are publically available from stock centres such as
the Bloomington Drosophila Stock Centre. One of the most
commonly used genetic tools in Drosophila is the bipartite
UAS/GAL4 tissue-specific expression system. GAL4 is a yeast
transcription factor that transactivates the expression of a
gene placed downstream of its cognate DNA sequence, the
upstream activation sequence (UAS). This allows one to
drive the expression of any gene (placed in a transgene
downstream of a UAS sequence and a basal promoter)
in a cell/tissue-specific manner when GAL4 is expressed
in that cell/tissue (under the control of a cell-specific
promoter) [19]. An enormous number of cell/tissue-specific
GAL4 driver transgenic flies have been created that can
be used to express UAS-transgenes, including UAS-tau, in
single cells, cell subsets, or entire tissues. More recently,
variations of this expression system have been developed
which give the experimenter increased resolution to regulate
gene expression in defined cells/tissues (e.g., Split GAL4 and
Intersection GAL80/GAL4 systems [20, 21]) and also allow
for combined spatial and temporal control of gene expression
(e.g., TARGET [22] and GeneSwitch [23, 24]). The TARGET
system has been recently employed in Drosophila models of
tauopathy to study the significance of tau aggregation [25].
In brief, the TARGET system uses a temperature-sensitive
variant of the yeast GAL4-repressor, (GAL80TS), expressed in
all cells by a ubiquitous tubulin promoter. AsDrosophila does
not regulate its body temperature, incubation temperature
can be used to control tissue-specific GAL4 activity. At 29-
30◦C, GAL80TS is deactivated (in restrictive conditions) and
permits GAL4-mediated expression of UAS-transgenes. At
18◦C in contrast, GAL80TS functions normally (in permissive
conditions) and potently represses GAL4/UAS activity [22].
Using this system, Colodner and Feany [25] initially reared
UAS-tau transgenic flies at 29◦C to restrict GAL80TS and
permit GAL4/UAS-mediated expression of tau in order to
allow the formation of tau aggregates. Subsequently, flies
were transferred to a GAL80TS permissive temperature of
18◦C to block continued GAL4/UAS-mediated tau expres-
sion. The authors were thus able to investigate the long-term
pathological consequences of tau aggregates by stimulating
their formation and assessing neurodegeneration at time
points beyond the block on further tau expression. This
approach allowed them to draw important conclusions
pertinent to aggregate-based disease-modifying therapies
[25] (discussed in Section 2). Another very valuable tool in
the repertoire of the UAS/GAL4 expression system is the
recent generation ofUAS-dsRNAi responder lines which have
been made to more than 90% of the entire fly genome
(see Table 1; collections available at the Vienna Drosophila
Research Centre, The Harvard Drosophila RNAi Resource
Project, and the NIG-FLY Stock Centre). These flies can be
crossed with UAS-tau-expressing transgenic flies to enable
tissue-specific knockdown of proteins that may interact
with tau in order to dissect their role in mediating tau
pathogenesis. This system can be used in conjunction with
the TARGET system to provide additional temporal control
over protein downregulation. The UAS-dsRNAi technology
can also be used in unbiased studies in which the function
of unknown genes that have appeared in human genetic
association studies can be rapidly tested. Even before this
technology was developed, there was precedence for this
approach when mutations in presenilins were associated
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with familial forms of AD, and the function of presenilin
was uncovered in Drosophila and C. elegans by studying
the invertebrate homologue [26]. Functional screening, in
Drosophila models of tauopathy of loci, identified in human
genomewide association studies has already begun [27].
An additional highly valuable resource for tau biologists
using Drosophila is the vast number of mutant fly stocks
which have been generated as a result of the extensive
use of Drosophila over decades. These stocks can allow
tau biologists to ask hypothesis-driven questions about
pathways which may be implicated in the pathogenesis
of tauopathies. For example, tau is hyperphosphorylated
in all tauopathies and one of the kinases believed to be
responsible for this aberrant phosphorylation is glycogen
synthase kinase beta (GSK-3β) (reviewed in [73]). Clearly,
an understanding of how pathways regulating GSK-3β
activity become dysregulated is necessary. In this context,
Drosophila provides valuable tools because many mutant
alleles of fly GSK-3β shaggy—sgg) have been generated as
well as alleles in the wingless and insulin signalling pathways
within which GSK-3β functions. Numerous studies have
taken advantage of these mutants by crossing them with
transgenics expressing wild-type or mutant human tau and
assessing the impact on downstream tau phosphorylation,
toxicity, and dysfunction [29, 74]. Not only have such studies
highlighted the importance of such pathways in mediating
tau phenotypes, but they have also paved the way for
exploring disease-modifying therapeutic interventions [47].
If for any reason a novel transgenic fly needs to be
generated, this is a relatively straight forward, rapid, and
inexpensive task. The transgenesis process (described in
more detail in Pandey and Nichols 2011 [12]) usually takes
less than 6 weeks and is highly cost-eﬀective. Novel tau
transgenic flies have been generated and used. For example,
the Feany laboratory and others have generated a number
of fly lines expressing human tau with point mutations at
various phosphorylation sites, as a tool to investigate the
importance of these sites for tau toxicity [30, 31, 75].
Overall, the sophisticated genetic tools together with the
vast number of mutant fly stocks that already exist make it
relatively easy to study tauopathies in Drosophila. Using this
system, it is possible to genetically manipulate virtually any
physiological pathway-implicated tauopathies and examine
their role in the disease process.
1.1.3. Drosophila Is Relatively Simple and Yet Participates in
Complex Behaviours. Another outcome of the extensive use
of Drosophila as a laboratory model is that much is known
about its anatomy and physiology. It is clear that though this
organism is more complex than the other commonly used
invertebrate model, C. elegans, it is still somewhat simple,
both at the cellular and molecular level, when compared
to higher vertebrate models. For example, Drosophila has
fewer isoforms of many proteins (there are 6 isoforms of
tau in humans, 3 in rodents, and only 1 in Drosophila
[76]). The organisation of Drosophila’s neuronal systems
is also relatively simple. For example, the neuromuscular
system of Drosophila larvae comprises 30–40 motor neurons
that innervate 30 muscles per hemisegment, in 12 mostly
identical segments [77]. Also, the neuromuscular junctions
(NMJs) are easily visualised and well-studied structures
(reviewed in Budnik and Gramates 1999 [78]). Such sim-
plicity makes Drosophila amenable to experimentation at the
level of individual easily identifiable cells whilst still enabling
the investigation of functional (including behavioural) out-
comes of such manipulations. We have previously utilised
this simple NMJ system of Drosophila larvae to investigate
the eﬀects of highly phosphorylated tau on the structure and
function of the NMJ on muscle 4 [48].
Despite its relative simplicity compared to other model
organisms, Drosophila is capable of participating in “higher
complex behaviours” such as courtship behaviour [79],
learning and memory [80], social interactions [81], aggres-
sion [82], grooming [83], and even alcohol preference and
addiction [16]. This makes it amenable to cognition-centred
functional assays that are particularly relevant when mod-
elling human neurodegenerative diseases like Alzheimer’s
disease, characterised by progressive loss of complex cogni-
tive processes such as learning and memory. Indeed, some
groups have utilised learning and memory assays to assess
the impact of tau expression in their Drosophila models
of tauopathy; Mershin et al., demonstrated that associative
learning and memory processes were significantly compro-
mised in transgenic flies expressing human tau, bovine tau,
or even extra copies of Drosophila tau [51]. These results
clearly showcase how this experimental paradigm can be
used for dissecting the mechanisms responsible for learning
and memory defects in the early stages of tauopathies like
Alzheimer’s disease.
1.1.4. Imaging Physiological and Pathological Events In Vivo
in Drosophila. Drosophila larvae have a clear cuticle and
the musculature beneath is richly innervated with a well-
characterised network of motor and sensory neurons. It is
therefore possible to visualise, in real time, the activity of
any physiological or pathological process that occurs within
these neurons as long as one is able to fluorescently tag one
of the proteins that is participating in that cellular process.
We exploited this attribute of Drosophila when we tested
the long-standing “tau and microtubule” hypothesis in our
Drosophila model of tauopathy. This hypothesis stemmed
from observations made in in vitro experimental paradigms
which led to the suggestion that hyperphosphorylated tau
exhibits reduced microtubule binding and would result in
breakdown of cytoskeletal integrity and disruption of axonal
transport (reviewed in Cowan et al., 2010 [84]). The rodent
models of tauopathy that existed at that time were not
amenable to analysis of axonal transport in vivo so our study
in Drosophila was the first to test this hypothesis in vivo.
We visualised axonal transport in real time in living intact
third instar larvae, by using the UAS/GAL4 system to drive
expression of GFP tagged neuropeptide Y and a wild-type
isoform of human tau (0N3R- which is constitutively highly
phosphorylated) within the motor neurons that run beneath
the transparent larval cuticle. As predicted by the “tau-
microtubule hypothesis”, we found that the expression of
highly phosphorylated tau led to a breakdown of microtubu-
lar integrity, causing axonal transport disruption, synaptic
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dysfunction, and locomotor impairment [47, 54]. Thus by
using Drosophila, we were able to test all aspects of this
hypothesis in vivo for the first time.
1.1.5. Drosophila Is Amenable to Medium-to-High Through-
put Enhancer/Suppressor Screens. It is relatively simple to
establish an enormous number of diﬀerent crosses between
flies. This, coupled with the fact that there are numerous
readouts of tau-mediated neuronal toxicity and dysfunc-
tion in Drosophila models of tauopathy, makes Drosophila
particularly well suited to unbiased, in vivo genetic, or
pharmacological enhancer/suppressor screens. The advent
of digital tracking technologies which enable one to track
behavioural parameters of Drosophila adults and larvae
in a semiautomated manner [85] should make Drosophila
models even more amenable to medium-to-high through-
put screening. As discussed in Section 1.2.2, the genetic
enhancer/suppressor screens that have been conducted on
Drosophila models of tauopathy have identified both previ-
ously suspected proteins (like PAR-1 kinase—[32]) as well as
novel modifiers (such as components of the JAK/STAT fam-
ily [25]). Extensive pharmacological enhancer/suppressor
screens have not been reported in Drosophila models of
tauopathy, but have been carried out to identify a handful
of lead compounds in Drosophila models of Huntington’s
Disease and other Fragile X syndrome (reviewed in Newman
et al., 2011 [86] and Pandey and Nichols 2011 [12]).
We have recently carried out a targeted pharmacological
enhancer/suppressor screen to validate the modulatory role
of a few compounds believed to interfere with protein-
folding pathways implicated in tauopathies [85].
1.2. DrosophilaModelsof Tauopathies (Summarised inTable 1)
1.2.1. How Have Tauopathies Been Modelled in Drosophila?.
Tauopathies are characterised by aggregates of abnormally
phosphorylated andmisfolded wild-type (wt) or mutant tau.
To model tauopathies therefore, most studies have utilised
the UAS-GAL4 expression system to target the expression
of either wt or mutant human (and even bovine, rodent,
and Drosophila) tau to specific neuronal or glial cells in
both larvae and adult Drosophila. In many of these studies,
the human tau expressed is highly phosphorylated, with
some studies reporting that it also becomes misfolded and/or
insoluble [33, 34, 53]. In general, the tau does not seem to
aggregate into bona fida, EM-verified tau filaments, unless
it is coexpressed with an enhancer [29], or expressed in glia
[25], (see Section 2.2). The consequences of tau expression
have then been investigated both by assessing neuronal
function (including axonal transport, synaptic function,
olfactory learning, and locomotor behaviour) and neuronal
death (in assays such as the rough-eye phenotype, CNS
neurodegeneration, and loss of notal bristles).
1.2.2. How Have Drosophila Models Been Used to Dissect
Disease Mechanisms? . Some of these models have been
used in unbiased genetic enhancer/suppressor screens to
identify proteins that interact with tau. Shulman and Feany
were the first to report the results of a forward genetic
screen looking for modifiers of the rough eye phenotype
induced by the expression of V337M human tau [32]. In
this screen, they identified both enzymes already implicated
in tau phosphorylation (like PAR-1 kinase and PP2A phos-
phatase) and apoptosis as well as proteins that had never
previously been implicated in tauopathies. These included
Drosophila homologs of mammalian proteins such as Ataxin-
2 and Glypican as well as cytoskeletal proteins Filamin and
MAP1b. Four synaptic cytoskeletal components were also
identified in a similar enhancer/suppressor screen together
with molecular cochaperones, a tyrosine phosphatase, ion
transporting ATPases, and RNA binding proteins as well as
transcriptional cofactors [35]. Again, though some of these
were expected to modulate the tau phenotype, others were
novel modifiers, whose role in the disease process has still
not been thoroughly examined.
These enhancer/suppressor studies are often accompa-
nied by complimentary experiments in which the identified
genes are either coexpressed with human tau [32, 34], or their
endogenous orthologs are genetically or pharmacologically
suppressed. This enables the verification of their role in tau-
mediated toxicity. For example, in their screen, Colodner
and Feany identified a suppressor of JAK/STAT signalling
as a modulator of glial tau toxicity in their model. They
went on to verify this by demonstrating that coexpression
of activators of JAK/STAT suppressed, whereas inhibitors of
JAK/STAT enhanced glial-tau-mediated toxicity [25].
In some studies, the Drosophila tauopathy models were
used in biased hypothesis-led experiments to dissect mecha-
nisms by which tau mediates dysfunction or toxicity. These
included testing of hypotheses about abnormal tau-driven
loss of function or gain of toxic function and the role of
tau phosphorylation and aggregation in these pathogenic
events. These studies investigated the eﬀects of abnormal
tau on (a) microtubular cytoskeletal structure and function
[36, 37, 54], (b) on synaptic structure and function [34,
48], (c) neurite outgrowth [38], (d) endogenous proteins
including Drosophila tau [54], (e) lysosomal function [39,
55], and (f) the cell cycle [40]. They have also highlighted
the relationship between abnormal tau and oxidative stress
[56] and alluded to mechanisms of tau turnover [34, 57, 87].
Some studies have also investigated the relationship between
tau and Aβ in Drosophila [41, 58, 74, 88]. These studies
have provided valuable insights into the possiblemechanisms
by which abnormalities in tau cause neurodegeneration in
tauopathies.
2. What Insights About Tauopathy Have We
Gained from Drosophila Models?
One of the critical obstacles to developing disease-modifying
therapies for the treatment of tauopathies is our incom-
plete understanding about disease pathogenesis. Drosophila
models of tauopathy have provided insights into some of
these pathogenic processes including mechanisms of toxicity,
mechanisms of tau turnover, and identification of pathways
by which tau and Aβ may interact. They have also raised
questions about the significance of tau aggregation. Gener-
ally, these insights add to those obtained from similar rodent
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models of tauopathies but in some instances Drosophila
models, by virtue of the elegant genetics tools available, are
able to more tightly correlate pathogenic events to causative
changes in tau. The fact thatDrosophilamodels are amenable
to genetic enhancer/suppressor screens, has further enabled
the identification of novel players in the disease processes.
2.1. Mechanisms of Tau Toxicity
2.1.1. Expression of Abnormal Tau Causes Neuronal Death.
The expression of wild-type or FTDP-17 mutant human
tau in the Drosophila eye causes cell death which gives rise
to the well-characterised “rough-eye phenotype” [32, and
others]. Neuronal death following the expression of wild-
type (0N4R and 2N4R) or mutant (V337M and R406W)
human tau in other neuronal populations including cholin-
ergic neurons, sensory neurons (including notum bristles),
andmushroombodies has also been reported [38, 50, 53, 59].
In some studies, human tau expression has been limited to
specific neuronal or glial populations, whereas in others it
is expressed panneuronally or expressed in both neurons
and glia. Irrespective of the cellular population the tau is
expressed in, neurotoxicity has been reported in many of
the models in both a cell autonomous and nonautonomous
manner. This toxicity is unlikely to be simply because the tau
is human, as similar neurodegeneration has been reported
following the expression of bovine tau, rodent tau, or even
overexpression of Drosophila tau [42, 50, 59]. This suggests
that excessive or misexpression of tau proteins is toxic,
irrespective of the host species from which the tau is derived.
One might speculate as to why expression of wild-type
(as opposed to disease causing mutant) tau should cause
toxicity—tau is normally expressed in all neurons and its
presence is not toxic in normal healthy cells. Though there
is clearly a dosage eﬀect [49], an imbalance in the normal
tau isoform ratios following the expression of exogenous
tau may be one cause of toxicity because some FTDP-17
splice mutations cause neurodegeneration simply by altering
the ratio of 3R to 4R tau isoforms in the brain. It is also
possible that the phosphorylation state of tau changes when
its expression equilibrium is changed and since this has
been shown to be critically involved in the mechanisms by
which tau causes toxicity (and dysfunction), as discussed
below, this may provide one explanation for why ectopic
expression of wild-type tau leads to neurodegeneration. In
this regard, these models recapitulate sporadic tauopathies
where the trigger for the conversion of normal wild-type tau
to a hyperphosphorylated and misfolded state is not clear.
The cellular mechanism by which high tau expression
causes neuronal death is not entirely understood. However,
more than one toxic mechanism may play a role since a
variety of morphological changes have been described in
the dying human-tau-expressing cells. Aﬀected neurons have
been shown to exhibit signs of both necrotic and apoptotic
degeneration. Williams et al., (2000) expressed various tau
transgenes (human wild-type 0N3R, bovine, and rodent) in
larval sensory neurons and reported degeneration charac-
terised by abnormal axon bundling, reduced arborisation,
axonal swelling, and beading; in severely aﬀected animals
there was also a clear loss of axonal projections [50]. A
number of studies expressing wild-type or mutant 4R tau
have reported vacuolization and abnormal swelling of nuclei
in adult brain and retina [29, 40, 51, 53]. There is also
evidence that apoptosis occurs in the human-tau-expressing
cells. TUNEL-positive cells have been reported in models
expressing wild-type and mutant tau in neurons and glia
[25, 40, 43]. Furthermore, coexpression of two inhibitors
of apoptosis, p35 and thread-suppressed V337M-mediated
rough-eye phenotype, whilst the Drosophila homology of
Fem1, an apoptosis activator exacerbated this phenotype in
two diﬀerent Drosophila models of tauopathy [32, 42]. To
identify how aberrant tau triggers apoptosis, Khurana et al.,
(2006) demonstrated that cell cycle activation occurs in the
brains and eyes of transgenic mice expressing wild-type or
mutant human tau, and that this occurs downstream of tau
phosphorylation and activates apoptosis [40]. Collectively,
all these studies indicate that activation of apoptosis may be
one of the mechanisms by which tau causes neurodegenera-
tion. Apoptotic cell death is also implicated in the pathogenic
mechanisms of other chronic neurodegenerative diseases like
Parkinson’s disease and Huntington’s disease.
Like apoptosis, oxidative stress is believed to play a
role in many chronic neurodegenerative diseases. Studies in
Drosophila imply that it may also be involved in the mecha-
nism by which aberrant tau mediates toxicity in tauopathies.
Dias-Santagata et al., (2007) [56] demonstrated that partial
inactivation of antioxidant pathways in flies expressing
R406W tau exacerbated the neurodegenerative phenotype
in their model. Moreover, the antioxidant Vitamin E sup-
pressed, whilst treatment with the prooxidant mitochondrial
toxin paraquat, exacerbated these phenotypes. These results
suggest that the expression of aberrant tau triggers oxidative
stress which may then contribute to the mechanism by which
the tau expressing neurons are degenerating.
It has traditionally been thought that the aggregates of
tau (filaments and tangles) are in themselves toxic and thus
are responsible for neurodegeneration in tauopathies. This
view is now being challenged (Section 2.2). However, since
glial expression of human tau in one Drosophila model
of tauopathy led to the formation of glial tangles, it is
conceivable that these were responsible for the tau-mediated
neurodegeneration described in that model [25]. However
transferring these flies to a temperature which repressed tau
expression, led to a dramatic reduction in the number of
TUNEL-positive cells without any change in the numbers
of glial tau tangles. This suggests that the aggregated tau is
not responsible for the tau toxicity observed in this model.
A similar observation has been made in a rodent model of
tauopathy—discussed in greater detail in Section 2.2 [89].
Even if aggregated tau does not play a critical role in tau-
mediated toxicity in Drosophila, misfolded (but soluble) tau
may be involved. Bilen and Bonini (2007) demonstrated
that components of the chaperone and ubiquitin proteosome
pathways [44], which are known to interact with misfolded
tau [90], potently suppressed the rough-eye phenotype
induced by either wild-type human tau or R406W tau. This
implies that the misfolded tau was mediating the toxicity
in their model. Further support for this idea comes from
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observations made by a few groups that when the expression
of human wild-type or mutant tau causes the rough-eye
phenotype, it is often MC1 or Alz50 positive—both of these
antibodies react with misfolded species of tau [53]. Thus it
would seem that, at least in Drosophila, tau does not need
to aggregate to cause degeneration. This raises the intriguing
possibility that tau aggregation is a late-stage event that
begins after the onset of neurodegeneration in tauopathies.
Another potential mechanism responsible for tau toxicity
is the displacement of tau from the axon to the soma. Tau is
classified as an axonal protein and its displacement into the
somatodendritic compartment is often considered by some
to be a pathogenic event culminating in tangle formation
and degeneration. One study from a Drosophila model of
a familial form of Parkinson’s Disease (PD) (which is a
secondary tauopathy since tau aggregates are often found
in this condition) lends support to this idea. In this model,
the expression of a disease causing mutant kinase (leucine
rich repeat kinase 2 or LRRK2) in adult brain dopaminergic
neurons causes degeneration of dendritic arborizations,
which is associated with a mislocalisation of the endogenous
Drosophila tau into the soma [52]. Furthermore, suppres-
sion of endogenous Drosophila tau using RNAi suppresses,
whereas exogenous overexpression of human wild-type tau
exacerbates, the mutant LRRK2-mediated dendritic degen-
eration. Similar results were reported by Zempel et al., in
primary culture [91]. They showed that degeneration of
dendritic spines following the exposure to Aβ oligomers was
associated with mislocalisation of tau from the axon to the
soma. Collectively, these results suggest that mislocalisation
of tau can cause degeneration. This may be one mechanism
responsible for degeneration in the Drosophila models of
tauopathy described above.
The role played by tau phosphorylation in mediating tau
toxicity has also been investigated in most of the Drosophila
models of tauopathy. In one of the early reports of tau-
mediated degeneration in the Drosophila nervous system,
Wittmann et al., reported a concomitant increase in tau
phosphorylation at the AT8 and AT100 sites [53]. This
implied that phosphorylation of tau occurs during tau-
mediated degeneration. Jackson et al., then demonstrated
that the loss of function of the Drosophila homolog of the
tau kinase GSK-3β, (shaggy) sgg, exacerbated, whilst the
coexpression of sgg with tau enhanced the human tau rough
eye phenotype [29]. Similarly, Yeh et al., [38] showed that
the loss of notal bristles in their model was diminished
when human tau was expressed together with a dominant
negative sgg. This implicates tau phosphorylation causally in
the degenerative process. This idea was corroborated by the
unbiased findings of the genetic enhancer/suppressor screen
carried out by Shulman and Feany in 2003, in which it was
seen that the largest class of modifiers of the V337M-induced
rough eye phenotype were tau kinases and phosphatases
[32]. However, the conclusive proof for the critical role
played by tau phosphorylation in tau-mediated neurotoxicity
was provided by Nishimura et al., in 2004 who employed fly
genetic tools to tightly correlate tau phosphorylation with
degenerating neurons [43]. Like Jackson et al., they first
demonstrated that the coexpression of a tau kinase (in this
case PAR-1 kinase, the Drosophila homolog of another tau
kinase MARK), with either wild-type or R406W mutant
human tau increases its phosphorylation at Ser262/Ser356
(the 12E8 site) and exacerbates the tau-mediated rough-
eye phenotype. They then went on to confirm that PAR-
1 phosphorylation of tau is essential for its toxicity by
demonstrating that tau nonphosphorylatable at this site (4R
tau with alanine substitutions at Ser262/Ser356) does not
cause degeneration in the eye [43] (this result was recently
reproduced by Chatterjee et al., [37]). Finally, they used
the MARCM expression system to generate PAR-1 mutant
clones in the human-tau-expressing flies and showed that
most of the cells that were TUNEL positive were in the PAR-
1/human tau clones (which were also 12E8 positive) [43].
Fulga et al., added further weight to the role of tau phos-
phorylation in tau toxicity by showing that the expression
of a pseudophosphorylated tau mutant (4RE14) was more
toxic, whilst a nonphosphorylatable mutant (4RAP) was less
toxic to retinal photoreceptors [30]. Tau phosphorylation
is also implicated in tau-mediated degeneration of other
CNS tissues. In the model used by Colodner and Feany
(2010), in which human wild-type tau is expressed in glia,
there is an age-dependent increase in tau phosphorylation
at some (AT8 and AT100) epitopes which coincides with
the increased tau insolubility/glial tangle formation and
apoptotic cell death they observe [25]. Kosmidis et al.,
showed that the 0N4R tau-mediated ablation of mushroom
bodies in the adult brain (due to a toxic eﬀect of tau
on mushroom body precursors) was enhanced by the
expression of a phospho-mimicking tau mutant (0N4RE14)
and suppressed by expression of a nonphosphorylatable tau
mutant (0N4RAP) [59]. Aberrant tau phosphorylation is also
believed to play a role in the mislocalisation of tau from
the axonal to somatodendritic compartments [52, 91]. Lin
et al., showed that the degeneration of dendrites which
occurred when tau mislocalised into the somatodendritic
compartment in their Drosophila model, was associated
with increased AT100 (Thr212, Ser214) immunoreactivity.
Moreover, the expression of a phospho-mutant form of
human tau which is not phosphorylatable at the AT100 site
led to an abrogation of the dendritic degeneration phenotype
and thus causally linked tau phosphorylation at this site with
the dendritic toxicity they observed [52].
In addition to the mechanisms discussed above, other
novel pathways and cellular processes may be involved in
mediating tau toxicity. Some of these have been identified
from genetic enhancer/suppressor screens and include the
JAK/STAT pathway [25]. This pathway is involved in a
variety of cellular processes including the transduction
of inflammatory signals. At the moment, the mechanism
by which this pathway mediates tau toxicity is unclear.
Nonetheless, it would seem that glial tau expression leads
to suppression of this pathway and that tau toxicity can
be rescued by increasing the expression or activity of
components of this pathway. Further investigation into this
pathway and the role it plays in tau-mediated toxicity
may lead to novel, glial-based therapeutic interventions not
just for glial cell centred tauopathies, but also for other
tauopathies. A second group of proteins that have previously
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not been extensively studied in the context of tau-mediated
toxicity are components of the actin cytoskeleton. These
were identified in the enhancer/suppressor screen carried
out by Blard et al., in 2006 [34]. Subsequently, Fulga et
al., demonstrated that human R406W tau interacts with F-
actin, leading to its abnormal bundling and accumulation,
and that genetic reduction of actin suppressed, whilst the
overexpression of actin exacerbated the V337M or wild-type
4R-mediated rough-eye phenotype in theirDrosophilamodel
[30]. Thus, crosstalk clearly occurs between constituents of
the axonal microtubular and synaptic actin cytoskeleton,
but how this is aﬀected when these components become
abnormal in tauopathies is unclear. This is certainly an area
worthy of investigation since it may be critically involved in
the mechanisms giving rise to the synaptic dysfunction/loss
which is evident in the early stages of tauopathies [92].
Indeed components of the actin network have been shown to
colocalise with NFTs in both AD and FTDP-17 brains [93].
2.1.2. Expression of Abnormal Tau Causes Neuronal Dysfunc-
tion. Though, as discussed above, there are many Drosophila
models demonstrating that expression of abnormal tau is
associated with neurotoxicity, there are other Drosophila
models which report behavioural phenotypes in the absence
of overt neurodegeneration. We have shown that expression
of wild-type human (0N3R) or Drosophila tau in larval
motor neurons causes neuronal dysfunction. This is char-
acterised by disruption of axonal transport and synaptic
structure and function [47–49, 54]. In our model, there
was no evidence of tau aggregation or neurodegeneration
so the tau-mediated neuronal dysfunction was caused by
a soluble tau species. Like us, Falzone et al., also report
axonal transport defects following expression of human
mutant (R406W) tau in their Drosophila model, which was
seen in the absence of neuronal death or tau aggregation
[60]. Analogous results have emerged from the laboratory
of Skoulakis who report significant learning and memory
deficits in transgenic flies expressing wild-type human tau
(2N4R), bovine tau, and Drosophila tau, before any evidence
of neurodegeneration [51] (Mershin et al., 2004). Similar
findings have been reported in a rodent model of tauopathy
in which aged mice expressing wild-type human tau (2N4R)
exhibited learning and memory impairments but in the
absence of overt neuronal loss [94].
Almost all the studies in which a soluble tau species
is associated with neuronal dysfunction in the absence of
degeneration implicate the phosphorylation state of the tau
in the causative mechanism. In our studies, we found that
reducing tau phosphorylation (at the PHF-1 and AT8 sites)
by treatment with LiCl suppressed, whilst increasing tau
phosphorylation by the coexpression of sgg, enhanced the
axonal transport and locomotor defects [47]. Kosmidis et
al., (2010) showed that the expression of a human 4R tau
phospho-mutant (2N4RSTA which cannot be phosphorylated
at Ser238 and Thr245) which is highly phosphorylated at the
AT100, AT8, pS262, and pS356, leads to profound memory
impairments in the absence of mushroom body degeneration
[59]. The results from rodent models of tauopathy (such as
Kimura et al., 2007 [94] described above), also suggest that
hyperphosphorylated tau plays a causal role in mediating
memory impairments seen in the absence of cell death or
tangle formation.
The mechanism by which highly phosphorylated tau
disrupts neuronal function is likely to involve a phosphoryl-
ation-mediated reduced ability of hyperphosphorylated tau
to bind to and stabilise microtubules. Highly phosphorylated
tau has been shown to have a reduced ability to bind
to microtubules in vitro [95]. In agreement with this, we
found that the breakdown of cytoskeletal integrity evident
in our Drosophila model occurred because the highly
phosphorylated (AT8 and PHF-1 positive) human (0N3R)
tau that we expressed was compromised in its microtubule-
binding ability [54]. Others too have shown that a significant
proportion of the human tau that is expressed in their
Drosophilamodel of tauopathy is not bound to microtubules
because it is highly phosphorylated [36]. Since highly
phosphorylated (AT8 positive) tau is evident in pretangle
neurons in AD brains, it is conceivable that the microtubular
cytoskeleton and thus axonal transport in these neurons
are compromised [96, 97]. This may be responsible for the
neural network disruptions that manifest as learning and
memory impairments in the early stages of disease.
An unexpected additional pathogenic eﬀect of soluble
highly phosphorylated human tau that we uncovered in our
model is that it binds to the endogenous Drosophila tau and
compromises its microtubule-binding ability as well. Thus,
the breakdown of cytoskeletal integrity that we reported pos-
sibly occurred because of functionally incompetent highly
phosphorylated human tau and the pathogenic conversion
of normal endogenous tau [54]. This ability of abnormally
phosphorylated soluble tau to bind to and functionally
compromise other proteins has been demonstrated in a cell
culture experimental model [98].
2.2. Significance of Tau Aggregation in Relation to Tau Toxicity.
Although misfolded protein aggregates characterise many
common proteinopathies including Alzheimer’s Disease,
Parkinson’s Disease, and Huntington’s Disease, the role that
they play in the disease process is debatable. Emerging
evidence from various models of these diseases suggests that
there is a dissociation between the aggregates themselves
and the underlying toxicity, and that instead the precursors
of the aggregates may be the toxic species. Drosophila
models of tauopathies have certainly contributed to this
argument by demonstrating that degeneration occurs in the
absence of overt tau aggregation. Williams et al., reported
degeneration of sensory neurons following expression of
human, bovine, or rodent tau in the absence of tangle
formation [50]. Subsequently, Wittmann et al., reported
neurodegeneration following expression of both human
wild type and FTDP-17 mutant tau, but here too in the
absence of tau aggregates [53]. These findings imply that in
these models of tauopathy, dysfunction and toxicity may be
caused by a soluble hyperphosphorylated tau. Virtually, all
Drosophila models of tauopathy have provided further proof
for this concept because in the majority of studies which
have expressed some form of tau in Drosophila, no insoluble
tau has been detected. We would argue that this does not
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necessarily indicate that Drosophila provides a poor model
of tauopathy; rather these studies furnished evidence that
tau aggregation is not necessary for tau toxicity ([50, 53]
and extended by many others). This conclusion has been
backed up by rodent studies. For example, mice expressing
wild-type human tau show behavioural deficits without
NFTs [94], and the triple-transgenic mice (expressing tau,
APP, and presenilin-1) also display neuronal dysfunction
before the formation of NFTs (and indeed before amyloid
plaques and cell death) [99]. Perhaps ironically, Drosophila
models have also provided insights into the mechanism by
which tau causes dysfunction early in the disease process,
without the “confounding” factors of insoluble tau and
cell death that are often encountered in rodent models. In
addition, as has been discussed elsewhere in this paper (see
Section 1.1), expressing diﬀerent forms of tau in specific
neuronal populations using the UAS/GAL4 system provides
numerous models to answer very specific questions, without
the need (or ability) for any one of these models to fully
recapitulate all aspects of disease.
One might wonder why there is no insoluble tau in
most fly models. In the case of models expressing tau in
motor neurons with the D42 driver [47–49, 54], in sensory
neurons [50], or in the mushroom body region of the brain
[51] the lack of insoluble tau might possibly be because
these models represent early neuronal dysfunction: if flies
lived longer, perhaps tangles and cell death would eventually
occur. However, in the case of models expressing tau in
photoreceptor neurons with the GMR, Sevenless or EY driver
[29, 32, 36, 39, 40, 43, 100] or in cholinergic neurons (Cha
driver) [53], or panneuronally with Elav driver [40, 53, 56]
this is clearly not so, because neurons die within the fly’s
lifetime without ever forming NFTs. In these retinal cell
death models, it could be suggested that perhaps flies lack the
molecular mechanisms necessary to create tangles. Again, we
know this is not so because the co-overexpression of the tau
kinase shaggy can force the production of tangles, even in this
retinal system [29], and because tau tangles can be formed in
glial cells of the fly [25].
As is implicit in the preceding paragraph, one key
phenomenon of tau toxicity that has been evident in fly
studies is the cell-type specificity of tau’s eﬀects on neurons.
It has long been apparent from the human conditions
that some cell types are more susceptible to tau pathology
than others [101]. Furthermore, human tauopathies and
numerous in vitro studies have shown that tau of diﬀer-
ent isoforms and diﬀerent phosphorylation states (not to
mention diﬀerent solubility states) can all behave quite
diﬀerently [102]. These phenomena can be investigated
precisely using the UAS/GAL4 system in Drosophila, as the
Skoulakis laboratory is doing, in a directed manner that is
rather diﬃcult in rodents. For example, in one study, they
directly compared the eﬀect of taus from diﬀerent species
expressed inmushroom body neurons on functional learning
and memory tasks—discussed in Section 2.5 [51]. They have
expressed a variety of disease-mutant tau constructs in a
variety of neuronal cell types [45], and discovered that the
taus are processed and posttranslationally modified quite
diﬀerently in diﬀerent neuronal types, as a function of the
regulation of kinases there. They subsequently found that
mushroom body neurons are more susceptible to wild type
tau than other neurons, but less susceptible to some of
the disease mutant taus [59]. Since tau aggregation can be
induced genetically in flies by coexpression of the relevant
kinases, one could use these genetic tools in Drosophila
to similarly investigate isoform and cell-type diﬀerences in
susceptibility to tau aggregation.
Where insoluble tau has been detected in fly, it does not
appear to be detrimental. In Chau et al.’s study older tau-
expressing flies developed insoluble tau (the precise nature of
which was unclear from their report) at 22 days of age; their
rough-eye phenotype was no worse than young flies without
insoluble tau [33]. This might suggest that the aggregates per
se are not detrimental. Dramatic and convincing evidence
that aggregated tau is not the major toxic species has come
from mice, in which reducing tau expression conditionally
in symptomatic mice can ameliorate the phenotype even
though tau tangles remain behind [89]. A similar approach
was recently taken in Drosophila, in a model in which wild-
type tau expression in glia causes neurofibrillary tangles
in glia and cell death of glia and neurons [25]. In this
study, when tau expression was turned oﬀ subsequent to
tangle formation, cell death was prevented though the
tangles remained. Drosophila might be a useful system to
extend these findings because of the possibility (through the
TARGET system and the of attB/attP integration system)
of replicating this experiment while also directly comparing
many species, isoforms, or alleles of tau.
Taken together, these results from the Drosophila models
of tauopathy are in agreement with the results obtained from
rodent models and cast doubt about the requirement of tau
aggregation in the pathogenesis of tauopathies. Instead, they
imply that a highly phosphorylated, soluble species of tau is
critically involved in the mechanisms that lead to neuronal
dysfunction and degeneration. Whether this represents the
state of aﬀairs in the early stages of disease only, and a second
set of degenerative events stimulated by tau aggregation takes
eﬀect at later stages of disease is yet to be determined.
2.3. Turnover of Tau. Protein quality control features prom-
inently in the discussion surrounding tauopathies and other
neurodegenerative diseases collectively termed ‘foldopa-
thies”. Protein quality control can be broadly thought to
encompass both systems that are activated when proteins
misfold, (such as the chaperone family and the unfolded
protein response (UPR)), as well as those that deal with
the clearance of terminally misfolded or aggregated proteins
(such as the autophagic/lysosomal systems and the ubiquitin
proteosome pathway (UPS)). Drosophila models of tauopa-
thy have demonstrated that tau interacts with all of these
pathways and that they may play a pivotal role in its turnover
in both normal and disease situations. These discoveries not
only impart information about the role of protein quality
control pathways in proteinopathies, they also highlight po-
tential therapeutic targets.
2.3.1. Tau May be Degraded By the Autophagy/Lysosomal
Pathway. It was suggested that tau could be cleared by the
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autophagic/lysosomal pathway when Berger et al., demon-
strated that Rapamycin, a known inducer of autophagy,
marginally suppressed the tau-mediated rough eye pheno-
type [100]. However, since the authors could not detect
human tau in their flies (possibly because of a weak
driver), they could not directly relate the suppression of
tau phenotype with autophagic clearance of tau. The more
conclusive proof that tau may be turned over by this pathway
and that a dysfunction in this process could play a role in tau-
mediated toxicity came from the results of Dermaut et al.,
[39] and Khurana et al., [55]. Both groups demonstrated
that lysosomal dysfunction, either through a loss of function
mutation of an endogenous lysosomal protein [39], or a
genetic reduction of the lysosomal enzyme cathepsin D,
potently exacerbated the human-tau-mediated phenotypes
in their respective models. Khurana et al., then went on
to show that though this lysosomal dysfunction was not
associated with an increase in the total tau levels, nor a
change in the phosphorylation state of tau, there was a five-
fold increase in the amount of caspase cleaved N terminal
truncated tau [55]. This form of tau was much more toxic
and insoluble than full length wild type or mutant tau.
These results suggest the tantalising possibility that normal
lysosomal function prevents tau from being cleaved by cas-
pases and thus prevent it from acquiring a more pathogenic,
aggregation-prone status. Whether lysosomal function in
healthy neurons protects tau by turning it over in a normal
pathway with little tau getting shunted down a “caspase
cleavage pathway” is not clear. Since both dysfunctional
lysosomes and truncated tau species have been detected in
AD brains (reviewed in Khurana and Feany (2007) [103]),
these findings provide an insight into potential mechanisms
that may trigger tau aggregation in tauopathies.
2.3.2. Tau Abnormalities May Trigger the Unfolded Protein
Response. The unfolded protein response (UPR) deals with
excess misfolded protein in the ER and aims to restore
homeostasis by reducing entry of such proteins into the
ER, stimulating the degradation of the misfolded/aggregated
proteins, or upregulating heat shock proteins (HSPs) and
other protein quality control genes. Loewen and Feany
(2010) recently demonstrated that the UPR is activated in
transgenic flies expressing human wild-type and mutant tau,
and that there is a positive correlation between the extent
of the UPR activation and the degree of toxicity [57]. The
fact that the greatest activation of the UPR was seen in flies
expressing a phospho-mimicking mutant form of tau led
the authors to speculate that excessively phosphorylated tau
was triggering the UPR activation. When components of
the UPR machinery were genetically suppressed to prevent
its induction, there was a strong exacerbation of the tau-
mediated phenotypes. These results imply that the unfolded
protein response occurs as a compensatory measure to
protect cells against abnormal, hyperphosphorylated, and
possible misfolded tau species. There is some evidence to
suggest that the UPR is activated in AD [104], but the fact
that misfolded and hyperphosphorylated tau species still
persist and cause neurodegeneration implies that it cannot
adequately deal with the abnormal tau.
2.3.3. The Chaperone/UPS System May Be Involved in the
Degradation of Phosphorylated Tau. Though there is a lot of
evidence from rodent and cell culture models of tauopathy
showing that chaperone proteins such as CHIP (C-terminus
of Hsc-70 interacting protein) regulate the turnover of
phosphorylated tau via the UPS [105], the evidence from
Drosophila is conflicting. Feuillette et al., reported that nei-
ther genetic downregulation, nor pharmacological inhibition
of the UPS increased the total level or phosphorylation state
of endogenous Drosophila tau. This prompted them to con-
clude that tau is not degraded by the UPS in Drosophila [87].
This was contrary to the findings of Blard et al., a year later,
that the inhibition of proteasomal activity in flies expressing
wild-type (0N4R) tau resulted in the accumulation of high-
molecular-weight tau species [34]. Moreover, in agreement
with the findings from rodent and cell culture models, they
found that preventing tau phosphorylation by expressing it
in a background of dominant negative sgg also led to an
accumulation of high molecular weight tau species. This
implies that UPS-led clearance of tau in their model was
dependent upon its phosphorylation state. With regard to
the role played by chaperones in the refolding and clearance
of tau, the results from Drosophila models are perplexing.
Shulman and Feany did not identify any member of the
chaperone family in their V337M tau-mediated rough eye
phenotype enhancer/suppressor screen in 2003 [32]. Nor
did they find any modulatory eﬀect of the coexpression
of hsp70 and hsc4, two molecular chaperones, on this tau
phenotype. In contrast, Blard et al., did identify molecular
chaperones in the enhancer/suppressor screen that they
carried out three years later. However when these chaperones
were coexpressed with V337M, they exacerbated the rough
eye phenotype in their model [34]. The significance of these
findings is not clear.
2.4. Aβ and Tau Interactions. The relationship between the
tau and amyloid pathologies and the pathways that facilitate
an interaction between them has been a matter of intense
debate and scientific research in this field. The general
consensus is that amyloid pathology lies upstream of tau
pathology and thus must activate cellular processes that
cause the hyperphosphorylation and aggregation of tau. The
results that have come forth from the few Drosophila models
of tauopathy that have attempted to study the interaction
between these two proteins broadly support this view.
Torroja et al., demonstrated in 1999 that the pan-
neuronal expression of either bovine tau or the Drosophila
homolog of amyloid precursor protein (APPL) results in
the retention of vesicles in larval motoneurons [58] (an
eﬀect also seen after expression of human APP [106]). This
phenotype becomes significantly more severe when both
are coexpressed implying that the two proteins interact to
cause a disruption of axonal transport. We reported a similar
result in 2010, when we found that coexpression of human
Aβ42 with wild-type human tau (4R) potently exacerbates
tau-mediated axonal transport disruption in larval motor
neurons [74]. We went on to show that the two proteins
interact to impair the locomotor ability of adult flies and
shorten their lifespan, and that these exacerbatory eﬀects
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can be prevented with LiCl. This implies that GSK-3β is
mediating the interaction between tau and Aβ42 in our flies.
More recently, Sofola et al., (2010) have provided more
evidence to suggest that Aβ may be activating GSK-3β in
their Drosophila model [88]. They used an inducible gene
expression system to express Arctic mutant Aβ42 specifically
in adult neurons and found that it accumulates with age
and causes increased mortality and a progressive neuronal
dysfunction in the absence of overt cell loss. This also
leads to an increase in GSK-3β activity. Interestingly, the
pathogenic eﬀects of Aβ42 in this model are significantly
suppressed when Aβ42 is expressed in a Drosophila tau null
line, demonstrating an interaction between the two proteins
in the pathogenic process [88]. This result supports the
observations made in various rodent models of tauopathy
that Aβ requires tau to mediate its pathogenic eﬀects [107]
(for amore comprehensive review seeMorris et al., 2011 [7]).
Other reports suggest that tau and Aβ/APP may interact
via other kinases. Wang et al., (2007) the demonstrated that
coexpression of human R406W tau with human APP leads
to an exacerbation of the tau-mediated rough eye pheno-
type which is suppressed by knocking down the tumour
suppressor protein LKB1 [46]. The authors suggest that APP
activates LKB1 to enhance PAR1-mediated phosphorylation
of human tau. This is because the coexpression of tau and
APP leads to an increased tau phosphorylation at the PAR1
site 12E8, which is diminished in flies in which LKB1 is
knocked down by RNAi. Iijima Ando and Iijima (2010) show
that Aβ42 exacerbates the rough eye phenotype induced by
the expression of human wild type (0N4R) tau, and that
this eﬀect is accompanied by an increased phosphorylation
of tau at a number of sites including Ser202, Thr231, and
Ser262[41]. The authors go on to show that the exacerbatory
eﬀect of Aβ42 on the tau rough eye phenotype is suppressed
if Aβ42 is coexpressed with a mutant form of tau which
cannot be phosphorylated at Ser262. This indicates that
Aβ42-mediated phosphorylation at this site is critical in its
pathogenic interaction with tau. The authors suggest that the
damage-activated check point kinase 2, whose RNA levels are
upregulated in their Aβ42 expressing flies, may be responsible
for mediating Aβ42’s eﬀects on tau [41].
Overall, the Drosophila models of tauopathy in which
both tau and Aβ/APP are coexpressed can provide valuable
insights into the cellular pathways that mediate the inter-
action between these two proteins. They can also serve as
useful platforms to screen the therapeutic agents designed to
interfere with this interaction.
2.5. Isoform Specific Diﬀerences. Alternative splicing of one
gene leads to the translation of 6 isoforms of tau in the
adult human brain, which diﬀer in the presence or absence
of 1 or 2 N-terminal domains and have either three (3R)
or four (4R) C-terminal microtubule binding domains. In
the adult brain, the ratio of 3R : 4R isoforms is 1. Rodents
have 3 isoforms of tau and Drosophila has one. All tau
isoforms, irrespective of host species, have in common the
microtubule binding domains and serve the same function.
In diﬀerent models of tauopathy, diﬀerent human tau
isoforms are expressed (either as wild type or harbouring
disease mutations), with usually no obvious reason given for
the choice of isoform. The results from Drosophila models
of tauopathy have demonstrated that diﬀerent tau isoforms
(even from the same host species) have diﬀerential abilities
to cause dysfunction and death. This could be because,
as has been demonstrated in vitro, they exhibit diﬀerent
interacting partners, diﬀerent microtubule binding abilities,
and diﬀerent susceptibilities to phosphorylation.
Chen et al., (2007) demonstrated that although the
expression of both wild type human tau (2N4R) and
Drosophila tau leads to the rough eye phenotype in
adult flies only about 50% of modifiers identified in
enhancer/suppressor screen alter the phenotype of both
Drosophila tau and human tau in the same way; the
remaining modifiers diﬀerentially modify the phenotype of
either one or the other [42]. This shows that though these
two species of tau are functionally similar and may interact
with the same proteins in toxic pathways, they do also
exhibit significant diﬀerences. Kosmidis et al., (2010) have
shown that whilst the expression of human wild-type 0N4R
tau and 2N4R tau caused a severe ablation of mushroom
bodies in adult fly brains, the expression of human wild
type 0N3R tau, bovine tau, and Drosophila tau have no
eﬀect [59]. Interestingly however, despite this lack of eﬀect
on the integrity of mushroom bodies, the expression of
bovine and Drosophila tau leads to learning and memory
impairments [10, 51, 65]. This clearly shows a strong isoform
specific eﬀect—some isoforms are directly toxic; others cause
profound dysfunction rather than overt neurotoxicity.
2.6. Tau Phosphorylation—One Size Fits All? . The insights
about the causal role of phosphorylation in the pathogenesis
of disease that have emerged from Drosophila models are
in agreement with those from rodent and other models.
However, the findings from Drosophila suggest that the
pathogenic consequences of tau phosphorylation are depen-
dent upon the site that is phosphorylated. Tau phospho-
rylation at some sites is associated with neurodegeneration
whereas phosphorylation at other sites is associated with
neuronal dysfunction in the absence of cell death. Phospho-
rylation of tau at the PAR kinase/MARK sites (Ser262/Ser356—
the 12E8 site) is associated with toxicity in the Drosophila
retina [37, 43] and mushroom bodies [59]. However in
the study of Nishiumra et al., where they found that the
expression of tau not phosphorylatable at the 12E8 site is
not toxic, they also noted a reduced phosphorylation at
the AT8 and AT100 sites, though significance of this in
relation to the toxicity is not clear. They also reported that
tau phosphorylation at the PHF-1 site (Ser396 Ser404) is not
dramatically reduced in flies expressing this phospho-mutant
tau and hence one may conclude that phosphorylation at
this site does not mediate toxicity [43]. This conclusion is
further strengthened by the findings of Chatterjee et al.,
(2009) who also generated that transgenic flies expressing tau
are not phosphorylatable at the PAR-1 (12E8) site [37], but
unlike Nishimura et al., [43] they coexpressed this with sgg.
This resulted in the phospho-mutant tau becoming highly
phosphorylated at AT8, AT100, and PHF-1, but interestingly,
it does not give rise to the rough eye phenotype. Moreover,
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when Chatterjee et al., expressed another tau phospho-
mutant, this time one is not phosphorylatable at GSK-
3β sites and coexpressed it with PAR-1, they saw a strong
12E8 signal and a severe rough-eye phenotype [37]. Taken
together, Chatterjee and Nishimura’s findings imply that tau
phosphorylated at the PAR-1/MARK sites (like 12E8) causes
neurodegeneration, whereas tau phosphorylated at the GSK-
3β sites (like PHF-1, AT8, AT180, and AT100) causes
dysfunction. In support for this we find that in our model,
where we do not see any neurodegeneration, manipulations
that increase phosphorylation of wild-type human (0N3R)
tau at GSK-3β sites exacerbate tau neuronal dysfunction phe-
notypes (such as axonal transport impairments, cytoskeletal
disruptions, and locomotor defects) whilst, treatment with
GSK-3β inhibitors rescues these phenotypes [47, 54]. In a
rodent model of tauopathy, Kimura et al., (2007) also report
an increased phosphorylation of tau at the PHF-1 site which
they associated with dysfunction rather than degeneration
[94]. Other tau phosphorylation sites which dissociate tau-
mediated toxicity from dysfunction are Ser238 and Thr245.
Kosmidis et al., (2010) reported that the expression of
a 2N4R human tau phospho-mutant which cannot be
phosphorylated at these sites suppresses the mushroom body
ablation that is usually seen following expression of 2N4R
tau, but does not abrogate the learning and memory impair-
ment that is also associated with its expression [59]. Their
finding that this phospho-mutant tau has elevated AT100
and AT8 immunoreactivity, suggests that phosphorylation at
these sites could be associated with dysfunction rather than
toxicity. However, since tau has been shown to be phosphory-
lated at these sites in degenerating neurons [53], one cannot
always conclude that occupation of these sites indicates
dysfunction and not toxicity. Perhaps the pathogenic eﬀect of
any phosphorylation site depends on the other sites occupied
on tau at the same time. Furthermore, the phosphorylation
profile may change temporally as the disease progresses
and dysfunctional neurons begin to degenerate, something
that will not be reflected or appreciated when studying the
phosphorylation patterns in the end-stage pathology.
3. How Do These Insights
Pave the Way for Disease-Modifying
Therapeutic Intervention?
An unanimous conclusion that one may draw from the
findings of Drosophila models of tauopathy is that a hyper-
phosphorylated, soluble species of tau plays a critical role in
causing neuronal dysfunction and degeneration. Therefore,
there is still a lot of potentials in identifying agents that may
reduce tau phosphorylation (some of which have already
been tested in Drosophila) and research eﬀorts in this area,
which are currently ongoing, are likely to yield disease
modifying therapeutics. Conversely, the findings from these
Drosophila models raise doubts as to the usefulness of anti-
tau aggregation strategies, at least in the early stages of
disease.
With regard to the mechanism by which hyperphos-
phorylated tau causes toxicity, the findings from numerous
Drosophila models suggest that tau triggers apoptosis, either
by triggering cell cycle activation or inducing oxidative stress.
This would suggest that disease modifying interventions
to prevent tau toxicity could investigate the usefulness of
antiapoptotic or antioxidant strategies. Antioxidant inter-
ventions have already shown promise in some Drosophila
models of tauopathy [56].
The Drosophila models of tauopathy that have focused
on hyperphosphorylated tau-mediated neuronal dysfunction
point to a tau-mediated breakdown of cytoskeletal integrity
in the causative mechanism. Disease modifying therapies
to counter this could investigate the utility of microtubule
stabilising agents, a target that is currently being investigated
in the rodent models of tauopathy [108].
The insights that have come forth so far from Drosophila
about tau turnover would imply that the pharmacological
activation of autophagy or the UPR may prove useful for the
removal of toxic, truncated, and hyperphosphorylated tau
species.
4. Conclusion
Drosophila models of tauopathy have only been used by tau
biologists for the last ten years, and in this time, they have
contributed to our understanding of the pathogenesis of
tauopathies in a number of ways: (a) they have been pivotal
in identifying novel players in the disease process as a result
of their amenability to unbiased genetic screens; (b) they
have highlighted potential mechanisms of tau-mediated cell
death and dysfunction and the significance of the various
tau abnormalities in that; (c) they have furthered our
understanding of tau turnover in normal and disease states.
Stemming from these insights are a number of possibilities
for disease-modifying therapeutic interventions, and here
too the fruit fly can contribute, by providing the platform
for such drug screens in a “whole organism context”. Overall,
the ease and experimental tractability of Drosophila position
it in an important preclinical stage of drug discovery where
the exploratory work on disease mechanisms as well as drug
testing on the identified pathways can be investigated in vivo.
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